查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1859999

曲前列尼爾藥物：全球市場佔有率和排名、總收入和需求預測（2025-2031 年）

Treprostinil Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 85 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年全球曲前列尼爾市場規模估計為 13.31 億美元，預計到 2031 年將達到 22.44 億美元，在 2025 年至 2031 年的預測期內，複合年成長率為 7.3%。

本報告對近期有關曲前列尼爾藥物跨境產業佈局、資本配置模式、區域經濟相互依存關係和供應鏈重組的關稅調整和國際戰略措施進行了全面評估。

曲前列尼爾是一種血管擴張劑，用於治療肺動脈高壓。

曲前列尼爾是一種穩定的三環類前列腺環素類似物，主要用於治療肺動脈高壓（PAH）。它能促進肺動脈血管擴張並抑制血小板凝集，從而改善患者的運動能力和生活品質。曲前列尼爾有多種劑型，包括靜脈注射、皮下注射、吸入和口服，以滿足不同疾病階段和耐受程度的患者的需求。自2002年獲得FDA核准以來，曲前列尼爾已成為治療PAH的重要選擇之一。

曲前列尼爾市場正經歷快速成長，主要歸因於以下幾個因素。首先，肺動脈高壓的盛行率不斷上升，尤其是在老年人族群中，這導致對有效治療方法的需求激增。其次，曲前列尼爾可透過多種給藥途徑給藥，這擴大了其治療範圍，並提高了患者的依從性。此外，政府對罕見疾病的支持（例如《孤兒藥法案》）也為曲前列尼爾的研發和商業化提供了有利環境。

儘管前景可觀，但曲前列尼爾藥物市場仍面臨諸多挑戰與風險。首先，曲前列尼爾生產流程複雜且高成本，限制了低收入地區的用藥。其次，其他前列腺環素類似物的競爭可能會影響曲前列尼爾的市佔率。此外，曲前列尼爾的副作用，例如注射部位疼痛，可能會影響患者的治療順從性。

曲前列尼爾藥物的下游需求主要集中在醫院和診所等醫療機構。隨著肺動脈高血壓(PAH) 患者數量的增加，對曲前列尼爾等有效治療藥物的需求持續成長。此外，醫療服務提供者擴大選擇先進且有效的藥物來改善患者的治療效果和生活品質。同時，醫療保險覆蓋範圍的擴大也提高了患者獲得曲前列尼爾的機會，從而增加了市場需求。

曲前列素尼爾的上游原料包括前列腺環素類似物及相關生物技術載體。前列腺環素類似物的萃取和合成是曲前列素尼爾生產的關鍵步驟，涉及複雜的化學和生物過程。生物技術的進步，例如基因工程和細胞培養技術，為前列腺環素環素類似物的生產開闢了新的途徑。然而，這些技術的應用也面臨成本和技術可行性的挑戰。

本報告旨在按地區/國家、類型和應用對全球曲前列尼爾藥物市場進行全面分析，重點關注總銷售量、收入、價格、市場佔有率和主要企業的排名。

曲前列尼爾藥物市場規模、估算和預測以銷售（千）和收入（百萬美元）為單位呈現，基準年為2024年，並包含2020年至2031年的歷史數據和預測數據。報告採用定量和定性分析相結合的方法，幫助讀者制定曲前列尼爾藥物的業務/成長策略，評估市場競爭，分析自身在當前市場中的地位，並做出明智的商業決策。

市場區隔

公司

  • United Therapeutics
  • Novartis
  • Teva
  • Zhaoke Pharma
  • Dr Reddy's Laboratories

按類型分類的細分市場

  • 雷莫杜林
  • 泰巴索
  • 奧雷尼特拉姆

應用領域

  • 醫院
  • 診所

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Treprostinil Drugs was estimated to be worth US$ 1331 million in 2024 and is forecast to a readjusted size of US$ 2244 million by 2031 with a CAGR of 7.3% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Treprostinil Drugs cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Treprostinil is a vasodilator that is used for the treatment of pulmonary arterial hypertension.

Treprostinil is a stable tricyclic prostacyclin analogue primarily used in the treatment of pulmonary arterial hypertension (PAH). It promotes vasodilation of pulmonary arteries and inhibits platelet aggregation, thereby improving exercise capacity and quality of life in patients. The drug is available in various formulations, including intravenous, subcutaneous, inhaled, and oral forms, catering to patients with different disease stages and tolerability. Since its FDA approval in 2002, treprostinil has become a significant therapeutic option for PAH.

The treprostinil drug market is experiencing rapid growth, driven by several factors. Firstly, the increasing prevalence of pulmonary arterial hypertension, particularly among the elderly population, creates a significant demand for effective treatments. Secondly, the availability of treprostinil in multiple administration routes expands its therapeutic applications and enhances patient compliance. Additionally, government support for rare diseases, such as orphan drug legislation, provides a favorable environment for the development and commercialization of treprostinil.

Despite the promising prospects, the treprostinil drug market faces several challenges and risks. Firstly, the complex and costly production process of treprostinil limits its accessibility in low-income regions. Secondly, competition from other prostacyclin analogs may impact treprostinil's market share. Furthermore, side effects associated with treprostinil, such as injection site pain, may affect patient adherence to treatment.

The downstream demand for treprostinil drugs is primarily concentrated in healthcare institutions such as hospitals and clinics. With the increasing number of PAH patients, the demand for effective treatments like treprostinil continues to rise. Moreover, healthcare providers are increasingly selecting advanced and effective medications to improve patient outcomes and quality of life. Simultaneously, the expansion of health insurance coverage enhances patient access to treprostinil, increasing its market demand.

The upstream raw materials for treprostinil include prostacyclin analogs and related biotechnological support. The extraction and synthesis of prostacyclin analogs are critical steps in treprostinil production, involving complex chemical and biological processes. Advancements in biotechnology, such as genetic engineering and cell culture technologies, offer new avenues for the production of prostacyclin analogs. However, the application of these technologies also presents challenges related to cost and technical feasibility.

This report aims to provide a comprehensive presentation of the global market for Treprostinil Drugs, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Treprostinil Drugs by region & country, by Type, and by Application.

The Treprostinil Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Treprostinil Drugs.

Market Segmentation

By Company

  • United Therapeutics
  • Novartis
  • Teva
  • Zhaoke Pharma
  • Dr Reddy's Laboratories

Segment by Type

  • Remodulin
  • Tyvaso
  • Orenitram

Segment by Application

  • Hospital
  • Clinic

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Treprostinil Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Treprostinil Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Treprostinil Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Treprostinil Drugs Product Introduction
  • 1.2 Global Treprostinil Drugs Market Size Forecast
    • 1.2.1 Global Treprostinil Drugs Sales Value (2020-2031)
    • 1.2.2 Global Treprostinil Drugs Sales Volume (2020-2031)
    • 1.2.3 Global Treprostinil Drugs Sales Price (2020-2031)
  • 1.3 Treprostinil Drugs Market Trends & Drivers
    • 1.3.1 Treprostinil Drugs Industry Trends
    • 1.3.2 Treprostinil Drugs Market Drivers & Opportunity
    • 1.3.3 Treprostinil Drugs Market Challenges
    • 1.3.4 Treprostinil Drugs Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Treprostinil Drugs Players Revenue Ranking (2024)
  • 2.2 Global Treprostinil Drugs Revenue by Company (2020-2025)
  • 2.3 Global Treprostinil Drugs Players Sales Volume Ranking (2024)
  • 2.4 Global Treprostinil Drugs Sales Volume by Company Players (2020-2025)
  • 2.5 Global Treprostinil Drugs Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers Treprostinil Drugs Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers Treprostinil Drugs Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of Treprostinil Drugs
  • 2.9 Treprostinil Drugs Market Competitive Analysis
    • 2.9.1 Treprostinil Drugs Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by Treprostinil Drugs Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Treprostinil Drugs as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Remodulin
    • 3.1.2 Tyvaso
    • 3.1.3 Orenitram
  • 3.2 Global Treprostinil Drugs Sales Value by Type
    • 3.2.1 Global Treprostinil Drugs Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Treprostinil Drugs Sales Value, by Type (2020-2031)
    • 3.2.3 Global Treprostinil Drugs Sales Value, by Type (%) (2020-2031)
  • 3.3 Global Treprostinil Drugs Sales Volume by Type
    • 3.3.1 Global Treprostinil Drugs Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global Treprostinil Drugs Sales Volume, by Type (2020-2031)
    • 3.3.3 Global Treprostinil Drugs Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global Treprostinil Drugs Average Price by Type (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Hospital
    • 4.1.2 Clinic
  • 4.2 Global Treprostinil Drugs Sales Value by Application
    • 4.2.1 Global Treprostinil Drugs Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Treprostinil Drugs Sales Value, by Application (2020-2031)
    • 4.2.3 Global Treprostinil Drugs Sales Value, by Application (%) (2020-2031)
  • 4.3 Global Treprostinil Drugs Sales Volume by Application
    • 4.3.1 Global Treprostinil Drugs Sales Volume by Application (2020 VS 2024 VS 2031)
    • 4.3.2 Global Treprostinil Drugs Sales Volume, by Application (2020-2031)
    • 4.3.3 Global Treprostinil Drugs Sales Volume, by Application (%) (2020-2031)
  • 4.4 Global Treprostinil Drugs Average Price by Application (2020-2031)

5 Segmentation by Region

  • 5.1 Global Treprostinil Drugs Sales Value by Region
    • 5.1.1 Global Treprostinil Drugs Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Treprostinil Drugs Sales Value by Region (2020-2025)
    • 5.1.3 Global Treprostinil Drugs Sales Value by Region (2026-2031)
    • 5.1.4 Global Treprostinil Drugs Sales Value by Region (%), (2020-2031)
  • 5.2 Global Treprostinil Drugs Sales Volume by Region
    • 5.2.1 Global Treprostinil Drugs Sales Volume by Region: 2020 VS 2024 VS 2031
    • 5.2.2 Global Treprostinil Drugs Sales Volume by Region (2020-2025)
    • 5.2.3 Global Treprostinil Drugs Sales Volume by Region (2026-2031)
    • 5.2.4 Global Treprostinil Drugs Sales Volume by Region (%), (2020-2031)
  • 5.3 Global Treprostinil Drugs Average Price by Region (2020-2031)
  • 5.4 North America
    • 5.4.1 North America Treprostinil Drugs Sales Value, 2020-2031
    • 5.4.2 North America Treprostinil Drugs Sales Value by Country (%), 2024 VS 2031
  • 5.5 Europe
    • 5.5.1 Europe Treprostinil Drugs Sales Value, 2020-2031
    • 5.5.2 Europe Treprostinil Drugs Sales Value by Country (%), 2024 VS 2031
  • 5.6 Asia Pacific
    • 5.6.1 Asia Pacific Treprostinil Drugs Sales Value, 2020-2031
    • 5.6.2 Asia Pacific Treprostinil Drugs Sales Value by Region (%), 2024 VS 2031
  • 5.7 South America
    • 5.7.1 South America Treprostinil Drugs Sales Value, 2020-2031
    • 5.7.2 South America Treprostinil Drugs Sales Value by Country (%), 2024 VS 2031
  • 5.8 Middle East & Africa
    • 5.8.1 Middle East & Africa Treprostinil Drugs Sales Value, 2020-2031
    • 5.8.2 Middle East & Africa Treprostinil Drugs Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Treprostinil Drugs Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Treprostinil Drugs Sales Value and Sales Volume
    • 6.2.1 Key Countries/Regions Treprostinil Drugs Sales Value, 2020-2031
    • 6.2.2 Key Countries/Regions Treprostinil Drugs Sales Volume, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Treprostinil Drugs Sales Value, 2020-2031
    • 6.3.2 United States Treprostinil Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Treprostinil Drugs Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Treprostinil Drugs Sales Value, 2020-2031
    • 6.4.2 Europe Treprostinil Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Treprostinil Drugs Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Treprostinil Drugs Sales Value, 2020-2031
    • 6.5.2 China Treprostinil Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Treprostinil Drugs Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Treprostinil Drugs Sales Value, 2020-2031
    • 6.6.2 Japan Treprostinil Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Treprostinil Drugs Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Treprostinil Drugs Sales Value, 2020-2031
    • 6.7.2 South Korea Treprostinil Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Treprostinil Drugs Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Treprostinil Drugs Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Treprostinil Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Treprostinil Drugs Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Treprostinil Drugs Sales Value, 2020-2031
    • 6.9.2 India Treprostinil Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Treprostinil Drugs Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 United Therapeutics
    • 7.1.1 United Therapeutics Company Information
    • 7.1.2 United Therapeutics Introduction and Business Overview
    • 7.1.3 United Therapeutics Treprostinil Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.1.4 United Therapeutics Treprostinil Drugs Product Offerings
    • 7.1.5 United Therapeutics Recent Development
  • 7.2 Novartis
    • 7.2.1 Novartis Company Information
    • 7.2.2 Novartis Introduction and Business Overview
    • 7.2.3 Novartis Treprostinil Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.2.4 Novartis Treprostinil Drugs Product Offerings
    • 7.2.5 Novartis Recent Development
  • 7.3 Teva
    • 7.3.1 Teva Company Information
    • 7.3.2 Teva Introduction and Business Overview
    • 7.3.3 Teva Treprostinil Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.3.4 Teva Treprostinil Drugs Product Offerings
    • 7.3.5 Teva Recent Development
  • 7.4 Zhaoke Pharma
    • 7.4.1 Zhaoke Pharma Company Information
    • 7.4.2 Zhaoke Pharma Introduction and Business Overview
    • 7.4.3 Zhaoke Pharma Treprostinil Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.4.4 Zhaoke Pharma Treprostinil Drugs Product Offerings
    • 7.4.5 Zhaoke Pharma Recent Development
  • 7.5 Dr Reddy's Laboratories
    • 7.5.1 Dr Reddy's Laboratories Company Information
    • 7.5.2 Dr Reddy's Laboratories Introduction and Business Overview
    • 7.5.3 Dr Reddy's Laboratories Treprostinil Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.5.4 Dr Reddy's Laboratories Treprostinil Drugs Product Offerings
    • 7.5.5 Dr Reddy's Laboratories Recent Development

8 Industry Chain Analysis

  • 8.1 Treprostinil Drugs Industrial Chain
  • 8.2 Treprostinil Drugs Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Treprostinil Drugs Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Treprostinil Drugs Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Treprostinil Drugs Market Trends
  • Table 2. Treprostinil Drugs Market Drivers & Opportunity
  • Table 3. Treprostinil Drugs Market Challenges
  • Table 4. Treprostinil Drugs Market Restraints
  • Table 5. Global Treprostinil Drugs Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Treprostinil Drugs Revenue Market Share by Company (2020-2025)
  • Table 7. Global Treprostinil Drugs Sales Volume by Company (2020-2025) & (K Units)
  • Table 8. Global Treprostinil Drugs Sales Volume Market Share by Company (2020-2025)
  • Table 9. Global Market Treprostinil Drugs Price by Company (2020-2025) & (US$/Unit)
  • Table 10. Key Manufacturers Treprostinil Drugs Manufacturing Base and Headquarters
  • Table 11. Key Manufacturers Treprostinil Drugs Product Type
  • Table 12. Key Manufacturers Time to Begin Mass Production of Treprostinil Drugs
  • Table 13. Global Treprostinil Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Treprostinil Drugs as of 2024)
  • Table 15. Mergers & Acquisitions, Expansion Plans
  • Table 16. Global Treprostinil Drugs Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 17. Global Treprostinil Drugs Sales Value by Type (2020-2025) & (US$ Million)
  • Table 18. Global Treprostinil Drugs Sales Value by Type (2026-2031) & (US$ Million)
  • Table 19. Global Treprostinil Drugs Sales Market Share in Value by Type (2020-2025)
  • Table 20. Global Treprostinil Drugs Sales Market Share in Value by Type (2026-2031)
  • Table 21. Global Treprostinil Drugs Sales Volume by Type: 2020 VS 2024 VS 2031 (K Units)
  • Table 22. Global Treprostinil Drugs Sales Volume by Type (2020-2025) & (K Units)
  • Table 23. Global Treprostinil Drugs Sales Volume by Type (2026-2031) & (K Units)
  • Table 24. Global Treprostinil Drugs Sales Market Share in Volume by Type (2020-2025)
  • Table 25. Global Treprostinil Drugs Sales Market Share in Volume by Type (2026-2031)
  • Table 26. Global Treprostinil Drugs Price by Type (2020-2025) & (US$/Unit)
  • Table 27. Global Treprostinil Drugs Price by Type (2026-2031) & (US$/Unit)
  • Table 28. Global Treprostinil Drugs Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 29. Global Treprostinil Drugs Sales Value by Application (2020-2025) & (US$ Million)
  • Table 30. Global Treprostinil Drugs Sales Value by Application (2026-2031) & (US$ Million)
  • Table 31. Global Treprostinil Drugs Sales Market Share in Value by Application (2020-2025)
  • Table 32. Global Treprostinil Drugs Sales Market Share in Value by Application (2026-2031)
  • Table 33. Global Treprostinil Drugs Sales Volume by Application: 2020 VS 2024 VS 2031 (K Units)
  • Table 34. Global Treprostinil Drugs Sales Volume by Application (2020-2025) & (K Units)
  • Table 35. Global Treprostinil Drugs Sales Volume by Application (2026-2031) & (K Units)
  • Table 36. Global Treprostinil Drugs Sales Market Share in Volume by Application (2020-2025)
  • Table 37. Global Treprostinil Drugs Sales Market Share in Volume by Application (2026-2031)
  • Table 38. Global Treprostinil Drugs Price by Application (2020-2025) & (US$/Unit)
  • Table 39. Global Treprostinil Drugs Price by Application (2026-2031) & (US$/Unit)
  • Table 40. Global Treprostinil Drugs Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 41. Global Treprostinil Drugs Sales Value by Region (2020-2025) & (US$ Million)
  • Table 42. Global Treprostinil Drugs Sales Value by Region (2026-2031) & (US$ Million)
  • Table 43. Global Treprostinil Drugs Sales Value by Region (2020-2025) & (%)
  • Table 44. Global Treprostinil Drugs Sales Value by Region (2026-2031) & (%)
  • Table 45. Global Treprostinil Drugs Sales Volume by Region (K Units): 2020 VS 2024 VS 2031
  • Table 46. Global Treprostinil Drugs Sales Volume by Region (2020-2025) & (K Units)
  • Table 47. Global Treprostinil Drugs Sales Volume by Region (2026-2031) & (K Units)
  • Table 48. Global Treprostinil Drugs Sales Volume by Region (2020-2025) & (%)
  • Table 49. Global Treprostinil Drugs Sales Volume by Region (2026-2031) & (%)
  • Table 50. Global Treprostinil Drugs Average Price by Region (2020-2025) & (US$/Unit)
  • Table 51. Global Treprostinil Drugs Average Price by Region (2026-2031) & (US$/Unit)
  • Table 52. Key Countries/Regions Treprostinil Drugs Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 53. Key Countries/Regions Treprostinil Drugs Sales Value, (2020-2025) & (US$ Million)
  • Table 54. Key Countries/Regions Treprostinil Drugs Sales Value, (2026-2031) & (US$ Million)
  • Table 55. Key Countries/Regions Treprostinil Drugs Sales Volume, (2020-2025) & (K Units)
  • Table 56. Key Countries/Regions Treprostinil Drugs Sales Volume, (2026-2031) & (K Units)
  • Table 57. United Therapeutics Company Information
  • Table 58. United Therapeutics Introduction and Business Overview
  • Table 59. United Therapeutics Treprostinil Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 60. United Therapeutics Treprostinil Drugs Product Offerings
  • Table 61. United Therapeutics Recent Development
  • Table 62. Novartis Company Information
  • Table 63. Novartis Introduction and Business Overview
  • Table 64. Novartis Treprostinil Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 65. Novartis Treprostinil Drugs Product Offerings
  • Table 66. Novartis Recent Development
  • Table 67. Teva Company Information
  • Table 68. Teva Introduction and Business Overview
  • Table 69. Teva Treprostinil Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 70. Teva Treprostinil Drugs Product Offerings
  • Table 71. Teva Recent Development
  • Table 72. Zhaoke Pharma Company Information
  • Table 73. Zhaoke Pharma Introduction and Business Overview
  • Table 74. Zhaoke Pharma Treprostinil Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 75. Zhaoke Pharma Treprostinil Drugs Product Offerings
  • Table 76. Zhaoke Pharma Recent Development
  • Table 77. Dr Reddy's Laboratories Company Information
  • Table 78. Dr Reddy's Laboratories Introduction and Business Overview
  • Table 79. Dr Reddy's Laboratories Treprostinil Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 80. Dr Reddy's Laboratories Treprostinil Drugs Product Offerings
  • Table 81. Dr Reddy's Laboratories Recent Development
  • Table 82. Key Raw Materials Lists
  • Table 83. Raw Materials Key Suppliers Lists
  • Table 84. Treprostinil Drugs Downstream Customers
  • Table 85. Treprostinil Drugs Distributors List
  • Table 86. Research Programs/Design for This Report
  • Table 87. Key Data Information from Secondary Sources
  • Table 88. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Treprostinil Drugs Product Picture
  • Figure 2. Global Treprostinil Drugs Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Treprostinil Drugs Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Global Treprostinil Drugs Sales Volume (2020-2031) & (K Units)
  • Figure 5. Global Treprostinil Drugs Sales Price (2020-2031) & (US$/Unit)
  • Figure 6. Treprostinil Drugs Report Years Considered
  • Figure 7. Global Treprostinil Drugs Players Revenue Ranking (2024) & (US$ Million)
  • Figure 8. Global Treprostinil Drugs Players Sales Volume Ranking (2024) & (K Units)
  • Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Treprostinil Drugs Revenue in 2024
  • Figure 10. Treprostinil Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 11. Remodulin Picture
  • Figure 12. Tyvaso Picture
  • Figure 13. Orenitram Picture
  • Figure 14. Global Treprostinil Drugs Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 15. Global Treprostinil Drugs Sales Value Market Share by Type, 2024 & 2031
  • Figure 16. Global Treprostinil Drugs Sales Volume by Type (2020 VS 2024 VS 2031) & (K Units)
  • Figure 17. Global Treprostinil Drugs Sales Volume Market Share by Type, 2024 & 2031
  • Figure 18. Global Treprostinil Drugs Price by Type (2020-2031) & (US$/Unit)
  • Figure 19. Product Picture of Hospital
  • Figure 20. Product Picture of Clinic
  • Figure 21. Global Treprostinil Drugs Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 22. Global Treprostinil Drugs Sales Value Market Share by Application, 2024 & 2031
  • Figure 23. Global Treprostinil Drugs Sales Volume by Application (2020 VS 2024 VS 2031) & (K Units)
  • Figure 24. Global Treprostinil Drugs Sales Volume Market Share by Application, 2024 & 2031
  • Figure 25. Global Treprostinil Drugs Price by Application (2020-2031) & (US$/Unit)
  • Figure 26. North America Treprostinil Drugs Sales Value (2020-2031) & (US$ Million)
  • Figure 27. North America Treprostinil Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 28. Europe Treprostinil Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 29. Europe Treprostinil Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 30. Asia Pacific Treprostinil Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. Asia Pacific Treprostinil Drugs Sales Value by Region (%), 2024 VS 2031
  • Figure 32. South America Treprostinil Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 33. South America Treprostinil Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 34. Middle East & Africa Treprostinil Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. Middle East & Africa Treprostinil Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 36. Key Countries/Regions Treprostinil Drugs Sales Value (%), (2020-2031)
  • Figure 37. Key Countries/Regions Treprostinil Drugs Sales Volume (%), (2020-2031)
  • Figure 38. United States Treprostinil Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 39. United States Treprostinil Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 40. United States Treprostinil Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 41. Europe Treprostinil Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 42. Europe Treprostinil Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 43. Europe Treprostinil Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 44. China Treprostinil Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 45. China Treprostinil Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 46. China Treprostinil Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 47. Japan Treprostinil Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 48. Japan Treprostinil Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 49. Japan Treprostinil Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 50. South Korea Treprostinil Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 51. South Korea Treprostinil Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 52. South Korea Treprostinil Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 53. Southeast Asia Treprostinil Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 54. Southeast Asia Treprostinil Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 55. Southeast Asia Treprostinil Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 56. India Treprostinil Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 57. India Treprostinil Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 58. India Treprostinil Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 59. Treprostinil Drugs Industrial Chain
  • Figure 60. Treprostinil Drugs Manufacturing Cost Structure
  • Figure 61. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 62. Bottom-up and Top-down Approaches for This Report
  • Figure 63. Data Triangulation
  • Figure 64. Key Executives Interviewed